Robert Nelsen

Sticking close to innovation roots, Arch Venture Partners raises oversubscribed $400M fund

Arch Venture Partners has operated longer than most venture capital firms by sticking close to its knitting.  And now the 28-year-old firm has even more cash to continue funding early-stage biotechnology, materials science and energy startups, capitalizing on a good run of late. The firm, with offices in Chicago, Seattle, Austin, San Francisco and Europe,… Read More

Image via Shutterstock

The top 10 biggest financing deals in the Pacific NW

Juno Therapeutics stunned the startup community earlier this week when it announced $134 million in venture funding, bringing total financing in the Seattle cancer research startup to $310 million. Amazingly, it raised all of that cash in less than 10 months. That got us wondering if Juno is the most heavily-funded startup in the Pacific… Read More


Cancer research startup Immune Design files for $60 million IPO

Immune Design Corp., a Seattle biotechnology company developing technologies to activate the body’s immune system to fight cancer, has filed to raise $60 million through an initial public offering. The company Like most biotech companies, Immune Design is losing money. It posted a net loss of $16 million last year, and has compiled an accumulated… Read More

Al Luderer

Seattle blood test startup Indi raises $47.25 million

Seattle’s life sciences industry is getting another boost. Integrated Diagnostics, a Seattle company developing blood-based proteomic tests, has raised $30.25 million in series B funding and $17 million in debt financing. Investors in the round include Baird Capital, InterWest Partners and the Wellcome Trust. The company, which operates under the name Indi, is led by… Read More


More funding for cancer research in Seattle: Adaptive Biotechnologies raises $105M

Researchers from Seattle who are finding ways to eliminate cancer are bringing in some serious funding today. On the same day the Fred Hutchinson Cancer Research Center announced a $20 million donation from the family of CEO Jeff Bezos, Seattle-based Adaptive Biotechnologies announced a big $105 million investment. Adaptive, which had previously only raised $15 million, was… Read More

Thong Le

Biotech investor Thong Le named CEO of Accelerator Corp.

Thong Le has taken the helm of Accelerator Corp., the Seattle-based investment firm that bankrolls emerging startups in the biotechnology arena. Le has served on the board of the organization for the past six years, but with the shift to CEO he will take over day-to-day operations at a critical time. First priority, Accelerator —… Read More


Money-losing Dendreon to cut 150 employees in bid to become ‘nimble’ biotech company

Once a rising star in Seattle’s biotechnology community, Dendreon Corp. announced Tuesday that it is reducing its staff by 15 percent in an effort to accelerate a path to profitability and operate “as a leaner, more nimble biotechnology company.” The cuts of about 150 people are the latest setback at Dendreon, which eliminated 500 jobs… Read More


Cancer research startup Immune Design pulls in $32.5 million, plans to raise more

Immune Design has reeled in $32.5 million in venture capital financing, with plans to raise up to $16.5 million more in the series C round if certain milestones are met. Investors in the round include The Column Group, Topspin Partners, as well as existing investors Alta Partners, Versant Ventures, Osage Partners and ProQuest Investment. “Immune Design… Read More


Tech Moves: Skype exec departs Microsoft; Frazier Healthcare taps new VC; etc.

—Skype executive Mark Gillett is leaving Microsoft, taking a new position at private equity firm Silver Lake, reports Kara Swisher at All Things D. Gillett previously worked at Silver Lake, and Swisher notes that he managed 2,500 developers. “Mark’s accomplishments at Skype have transformed the company,” said Silver Lake managing partner Egon Durban in a… Read More

Mitchell Gold

Ex-Dendreon CEO starts healthcare investment fund Alpine BioVentures

Former Dendreon CEO Mitch Gold has partnered with biotechnology stock researcher David Miller to create a new Seattle-based investment firm called Alpine BioVentures. The fund, which was started earlier this year, plans to invest in both public and private companies which are developing “significant innovations in healthcare technology which meaningfully improve the lives of patients.”… Read More


NanoString sets IPO range of $13-$15, plans to trade on Nasdaq under ticker NSTG

Seattle’s NanoString Technologies today set the terms for its upcoming initial public offering, with plans to sell shares in the range of $13 to $15 per share. The 138-person company, a maker of genomic analysis tools which spun out of genomics pioneer Leroy Hood’s Institute for Systems Biology in 2003, initially filed for an IPO last month…. Read More


Mobisante raises $4.2M for smartphone-based ultrasound imaging system

Mobisante, the Redmond-based company that makes ultrasound technology viewable on a smartphone or tablet, just pulled in $4.2 million in fresh funding to continue providing customers with a low-cost alternative to other expensive high-end portable ultrasound systems. Founded in 2009 by Sailesh Chutani — a former Microsoft mobile exec — and David Zar — a researcher at Washington… Read More


Medical device maker Ekos acquired in $180M deal

Ekos, a Bothell medical device maker whose catheter-based ultrasound devices are used to break up blood clots in legs, has been acquired by British pharmaceutical company BTG for $180 million. The deal also includes up to $40 million in additional payouts if milestones are met. In addition to Ekos, BTG also agreed to purchased Nordion’s… Read More

Bruce Montgomery

Bruce Montgomery biotech startup Cardeas Pharma raises $34 million

It has been a good week for the Seattle life sciences community. On Monday, Seattle genomics tool maker NanoString Technologies filed for an initial public offering that could raise up to $86 million. Now, comes word that Cardeas Pharma Corporation, a biopharmaceutical company led by Seattle biotech veteran Bruce Montgomery, has raised $34 million in funding…. Read More


Frazier buys pharmaceutical packaging company AndersonBrecon

Seattle venture capital firm Frazier Healthcare has joined with Philadelphia-based Packaging Coordinators to purchase AndersonBrecon, a leading contract pharmaceutical packing company. The unit had previously been owned by health services giant AmerisourceBergen Corporation. Packaging Coordinators is a portfolio company of Frazier, and the newly-combined entity will operate under the Packaging Coordinators name. “PCI has been on an aggressive… Read More


Theraclone raises $14M to ID rare human antibodies that could be used to fight disease

Seattle biotechnology company Theraclone Sciences has raised an additional $8 million in equity financing and $6 million in debt, bringing total investment in its series B funding to $50 million. Investors in the round included ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures, Versant Ventures and Zenyaku Kogyo. “Theraclone… Read More

Jim Olson

Blaze Bioscience raises $8.5M to help surgeons pinpoint cancer cells with ‘tumor paint’

Seattle biotechnology startup Blaze Bioscience has raised $8.5 million to continue developing technologies that  are designed to help surgeons more easily identify cancer cells in the body. Total funding in the company, with operations in the South Lake Union area of Seattle, now stands at $9.8 million. Blaze said that the money came from individual… Read More